Major Grant Awarded to Study PCLX-001 in Acute Myeloid Leukemia Patients
- Written by Newsfile
Edmonton, Alberta--(Newsfile Corp. - October 11, 2022) - Pacylex today announced that the US Department of Defense (DOD) awarded The University of Texas MD Anderson Cancer Center $1.4 million to treat Acute Myeloid Leukemia (AML) patients with PCLX-001, a first-in-class N-myristoylation inhibitor in clinical development by Pacylex. PCLX-001 is being studied in non-Hodgkin lymphoma (NHL) and solid tumor cancer patients at 4 clinical sites in Canada. This investigation will be the first of an N-myristoyl transferase (NMT) inhibitor, PCLX-001, in AML patients.
To view the full announcement, including downloadable images, bios, and more, click here[1].
Key Takeaways:
- PCLX-001, an N-myristoyl transferase (NMT) inhibitor, is being studied in non-Hodgkin lymphoma (NHL) and solid tumor cancer patients at 4 clinical sites in Canada.
- This clinical study is the culmination of work done in AML (Acute Myeloid Leukemia) animal models for years combining insights on the role myristoylation may play in cancer with an NMT inhibitor Pacylex licensed for exclusive development.
- This study in AML patients at MD Anderson will be the first clinical study of PCLX-001 in the US.
Click image above to view full announcement.
PCLX-001PCLX-001[2] (aka DDD86481) is a first-in-class, small molecule NMT inhibitor originally developed by the University of Dundee Drug Discovery[3] Unit as part of a program to treat African sleeping sickness, funded by Welcome Trust. Pacylex is developing PCLX-001 in the form of a once-a-day pill initially to treat leukemia and lymphoma. PCLX-001 has also been shown to inhibit the growth of lung and breast cancer tumors in animal models. In leukemia, lymphoma and breast cancer patients, the levels of NMT2 is correlated with survival, suggesting an important biological role in these cancers. In tests using cultured cancer cells in vitro, PCLX-001 is at least ten times as potent as ibrutinib (Imbruvica) and dasatinib (Sprycel), two clinically approved drugs currently used to treat hematologic malignancies.
About PacylexPacylex is a pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with a new first-in-class therapeutic, PCLX-001. Pacylex's technology combines new insights from Dr. Luc Berthiaume of the University of Alberta connecting myristoylation to cancer with a family of high quality myristoylation inhibitors Pacylex licensed from the University of Dundee. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex initiated clinical studies in Canada in the fall of 2021 in non-Hodgkin lymphoma and solid tumors. Pacylex is also receiving support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation.
For more information:Pacylex Pharmaceuticals Contact: Michael J. Weickert, Ph.DCEO, Pacylex Pharmaceuticals, Inc.E: michael.weickert@pacylex.com[4]P: 650-218-1840LinkedIn (www.linkedin.com/company/pacylex-pharma[5])Facebook (https://www.facebook.com/pacylex[6])Reportable page: (https://pacylex.reportablenews.com/[7])#cancer, #lymphoma, #leukemia, #albertacancer, #Pacylex, #PCLX001, #UAlberta; #UAlberta_FoMD; #Worldslongestgame
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/140132[9]
References
- ^ click here (www.newsfilecorp.com)
- ^ PCLX-001 (www.newsfilecorp.com)
- ^ University of Dundee Drug Discovery (www.newsfilecorp.com)
- ^ michael.weickert@pacylex.com (www.newsfilecorp.com)
- ^ www.linkedin.com/company/pacylex-pharma (www.newsfilecorp.com)
- ^ https://www.facebook.com/pacylex (www.newsfilecorp.com)
- ^ https://pacylex.reportablenews.com/ (www.newsfilecorp.com)
- ^ Pacylex (www.newsfilecorp.com)
- ^ https://www.newsfilecorp.com/release/140132 (www.newsfilecorp.com)